Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub
Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub
View: Text | PDF
Research Article Immunology

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

  • Text
  • PDF
Abstract

Tumor antigen–specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.

Authors

Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub

×

Figure 4

PD-1hiCD39+ CD4 Tconv TILs encompass tumor Ag–specific cells and respond to PD-1 blockade by enhancing DC-mediated CD8 T cell proliferation.

Options: View larger image (or click on image) Download as PowerPoint
PD-1hiCD39+ CD4 Tconv TILs encompass tumor Ag–specific cells and respond...
(A–C) Ex vivo isolated CD4+ TILs from one OC NY-ESO-1–seropositive patient were FACS-sorted into PD-1–CD39–, PD-1hiCD39–, and PD-1hiCD39+ CD4 Tconv (CD3+CD4+CD25-CD127+) subsets and cloned. (A and B) Clonal populations were stained and analyzed by flow cytometry. (A) PD-1 versus CD39 expression in clones representative of the 3 sorted Tconv populations. (B) Proportions of PD-1+ and CD39+ cells are summarized for all clones derived from PD-1–CD39– (n = 54), PD-1hiCD39– (n = 17), and PD-1hiCD39+ (n = 22) subsets. (C) IFN-γ concentration in the supernatant was quantified by ELISA for each clone stimulated with NY-ESO-1 peptide pool (fold increase over unstimulated condition) (n as in B). (D–F) Ex vivo CD4+ TILs (± anti–PD-1 mAbs pretreatment) were cocultured with iDCs in the presence or absence of PHA. (D) TNF-α, IFN-γ, IL-2, and IL-12 concentrations were quantified by CBA in the 24-hour supernatants (n = 3). (E) Histogram plots show CD154 expression in CD4 Tconvs after 6-hours stimulation. Proportions of CD154+ cells are summarized (n = 5). (F) Histogram plots show CD86 expression in DCs in day 2 cultures. MFI of CD86 staining are summarized (n = 4). (G) CD4+ TILs from OC NY-ESO-1–seropositive patients (± anti–PD-1 mAbs pretreatment); autologous iDCs and circulating CD8 T cells were cocultured in the presence of NY-ESO-1 peptides, stained with MHC-I/NY-ESO-1 peptide multimers on day 10, and analyzed by flow cytometry. Examples of dot plots show multimer staining and CD8 expression and proportions of multimer+CD8+ cells are summarized (n = 5). A 2-tailed paired t test was used to compare variables (E and F). Bonferroni’s correction was applied to account for multiple testing (E and F) and significance level was adjusted accordingly (*P < 0.016; **P < 0.0032). (E and F). Tconvs, conventional FOXP3- CD4 T cells; TILs, tumor-infiltrating lymphocytes; OC, ovarian cancer; iDCs, immature DCs; CBA, cytometric bead array.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts